News

Pfizer Inc. (NYSE:PFE) is one of the most promising low-cost stocks to buy now. On February 10, Bernstein maintained its Market Perform rating and $30 price target for Pfizer following a Q4 2o25 earnings report that exceeded expectations with $17.6 billion in revenue and $0.66 EPS. Despite strong financial results and a raised 2025 EPS […]

Pfizer reported positive Phase 2b results for its monthly GLP-1 obesity drug candidate PF-3944, with plans to run more than 20 clinical trials, including several focused on this asset. The FDA granted Priority Review for expanded use of HYMPAVZI in hemophilia A or B, potentially widening its eligible patient pool. These updates highlight fresh developments in obesity and hematology that go beyond routine product updates or earnings headlines. For investors tracking NYSE:PFE, these pipeline...

Pfizer Inc. (NYSE:PFE) is one of the best medical research stocks to buy according to hedge funds. Pfizer Inc. (NYSE:PFE) announced on February 6 that the U.S. Food and Drug Administration accepted and granted Priority Review for its supplemental Biologics License Application for HYMPAVZI® for the expansion of the approved indication to include treatment of […]

Pfizer's long-acting GLP-1 weight loss candidate could set the stage for a stock rally.

Insights from Kahn Brothers (Trades, Portfolio)' Fourth Quarter 2025 13F Filing

Pre-Market Stock Futures: Futures are trading higher after a wild Wednesday that saw the market rally hard on the open on the non-farm payrolls print that blew away estimates, despite a significant decline in government jobs. However, the “buy the rumor, sell the news” cliche came in fast and strong, quickly turning the rally into ... Here Are Thursday’s Top Wall Street Analyst Research Calls: BP Plc., Borg Warner, Generac, Kraft-Heinz, MercadoLibre, Pfizer, Shopify, Valvoline, and More

Pfizer (NYSE:PFE) received FDA Priority Review to expand HYMPAVZI to younger hemophilia patients and those with inhibitors. The company reported positive topline phase 2b results for its obesity drug candidate PF-3944 and plans to start multiple phase 3 trials in 2026. Both updates relate to large areas of unmet medical need in hemophilia and obesity care. For investors watching NYSE:PFE, these clinical updates arrive with the stock at $27.73 and a value score of 5. Over the past year, the...

It's worth taking a second look at the healthcare giant.

Pfizer reported strong earnings and earnings guidance. Large, unusual call option activity today, as noted in a Barchart report, indicates investors are bullish.

Pfizer Inc. (NYSE:PFE) is included among the Dividend Champions, Contenders, and Challengers List: 15 Highest Yielding Stocks. Pfizer Inc. (NYSE:PFE) reported its Q4 2025 results on February 3. The company posted revenue of $17.56 billion, falling slightly by 1.1% from a year earlier. On the earnings call, Chairman and CEO Albert Bourla asserted that the […]

Eli Lilly is priced for perfection thanks to its GLP-1 drugs, while Wall Street seems to have forgotten about these two high-yield healthcare stocks.

PFE bets on new and acquired drugs to reignite growth as COVID sales fade and a 2026-2030 patent cliff threatens key blockbusters.

Pfizer (NYSE:PFE) received FDA Priority Review for an expanded use of HYMPAVZI in younger and inhibitor-experienced hemophilia patients. Partnered antifungal Cresemba reached sales in Asia Pacific that triggered a milestone payment to Pfizer. Pfizer joined the BaseLaunch biotech incubator as a partner to work with early stage drug developers. Pfizer enters this news cycle with its shares at $27.05 and a mixed return profile, with a 13.6% gain over the past year, a 25.9% decline over three...